Figure 2 | Scientific Reports

Figure 2

From: Predicting treatment outcomes of intravitreal brolucizumab for polypoidal choroidal vasculopathy through noninvasive assessment of polypoidal lesion blood flow with optical coherence tomography angiography

Figure 2

Changes in average foveal thickness in eyes with polypoidal choroidal vasculopathy treated with 3 monthly intravitreal injections of brolucizumab followed by a treat-and-extend regimen with intravitreal brolucizumab. Foveal thickness (FT) was significantly reduced and maintained during the 1-year study period in both the group showing disappearance of blood flow signals and that without such findings (**P < 0.01). The FT reductions did not differ significantly between the two groups.

Back to article page